Lillys – Instametta

Lilly’s $7.8 Billion Bet Takes It Beyond Obesity Into Sleep

Scooping up Centessa gives Lilly a foothold in narcolepsy and a promising new class of wakefulness drugs. www.bloomberg.com #Lillys #Billion #Bet…

In the lucrative obesity drug race, there is Eli Lilly — and then there’s everybody else. A pair of headlines…

Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug…

Eli Lilly and Co. (NYSE:LLY) on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant…

Eli Lilly’s oral GLP-1 candidate, orforglipron, won’t earn approval as fast as the company expected. Meanwhile, a notable competitor is…

A next-generation obesity shot from Eli Lilly & Co. helped patients lose almost a quarter of their body weight, potentially making the…

Eli Lilly’s “triple g” drug helped patients lose about 28.7% of their body weight while also reducing pain associated with…

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time…

Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to…

Even by dramatically lowering the prices of some of its medications, the drug giant is still outpacing its rivals and…